Positron Corporation (POSC)

[zenvesting]

There's a lot of tough history here for this company and its shareholders, but the fact the company survived and positioned itself to benefit from the mainstream adoption of cardiac PET over the next couple of years could finally make it all worthwhile for the long suffering shareholders.

I accumulated the bulk of my position during the weakness the stock saw during 2018 tax loss selling under $0.05 and didn't put a single share up for sale during this recent spike to $1 because I believe these could be worth multiples more than $1 in a few years, once Flurpiridaz is approved and gives cardiac PET a clear advantage over SPECT (with it's clinical trial's last patient follow-up expected in August 2020) and good execution by Positron in making the most cost effective scanners for small and medium cardiac practices.

I'll continue to accumulate on any weakness, but hope to see the company begin to catch up with filings and relisting soon, so that we can watch their growth story begin to unfold over the next few years in public filings.